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Objective: It was previously determined that group‐based face‐to‐face
Mindfulness‐Based Cognitive Therapy (MBCT) and individual internet‐based MBCT
(eMBCT) are equally efficacious compared with treatment as usual (TAU) in reducing
psychological distress. In this study, the incremental cost‐utility of both interventions
compared with TAU was assessed.
Methods: This cost‐utility study included 245 self‐referred heterogeneous cancer
patients with psychological distress who were randomized to MBCT, eMBCT or
TAU. Healthcare costs and (informal) work‐related productivity losses were assessed
by interview. Outcomes were expressed in EuroQol‐5D‐3L utility scores and quality‐
adjusted life years (QALY). An economic evaluation with a time‐horizon of 3 months
was conducted from the societal perspective in the intention‐to‐treat sample. In addi-
tion, secondary explorative analyses of costs and quality of life during the 9‐month
follow‐up were conducted based on linear extrapolation of TAU.
Results: Paid work‐related productivity losses and societal costs were lower in both
intervention conditions compared with TAU during the 3‐month intervention period.
Moreover, quality of life (utility scores) improved in eMBCT versus TAU (Cohen's d:
.54) and MBCT versus TAU (.53). At a willingness to pay of €20000 per QALY, the
mean incremental net monetary benefit was €1916 (SD=€783) in eMBCT and
€2365 (SD=€796) in MBCT versus TAU. Exploration of costs demonstrated an equal
pattern of eMBCT and MBCT being superior to TAU. Quality of life at 9‐month
follow‐up remained improved in both interventions.
Conclusions: Results indicate that eMBCT and MBCT are cost‐saving treatments
whilst simultaneously improving quality of life for distressed cancer patients.
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Psychological distress is a negative emotional experience which
impedes coping with cancer and its treatment.1 Psychological distress
is highly prevalent in cancer patients2 and results in serious conse-
quences such as reduced quality of life, decreased compliance with
medical care, prolonged duration of hospital stay3,4 and increased
(inadequate) healthcare use.5 Although not all distressed cancer
patients subsequently wish for psychological treatment,6 the availabil-
ity of effective treatment for psychological distress in cancer patients
is required.
Psychological treatment in cancer patients yield small to medium
effects in reducing psychological distress.7 In addition to cognitive
behavioural therapy, mindfulness‐based interventions (MBIs)8,9 are
increasingly offered in oncological settings. Several randomized con-
trolled trials (RCTs) indicate that MBIs result in significant improve-
ments of depressive and anxiety symptoms in cancer patients, e.g.10-12
MBIs are usually offered as an eight‐week, face‐to‐face group
training. However, attending group‐based MBI is not always possible
for cancer patients.13 In contrast, Internet‐based interventions are
easily accessible, available 24/7 when delivered asynchronously and
save travelling time.14,15 A recent multicentre RCT in 245 self‐
referred heterogeneous cancer patients with (mild) psychological dis-
tress showed that both group‐based mindfulness‐based cognitive
therapy (MBCT) and individual internet‐based MBCT (eMBCT) had
a moderate effect in reducing psychological distress in comparison
with treatment as usual (TAU).11 The uncontrolled follow‐up period
of 9 months demonstrated consolidation of treatment effects in
both interventions.16
However, it remains unknown whether (e)MBCT provides value
for money.17 Evidence on cost‐effectiveness of MBIs is focused
mainly on depression.18A systematic review of economic evaluations
of 11 third‐wave cognitive behavioural interventions included 5 stud-
ies on MBIs, with two studies on MBIs in recurrent major depression
and single studies on MBIs in patients with multiple sclerosis, medi-
cally unexplained symptoms or cancer. Evidence on cost‐effectiveness
of MBIs in these populations was deemed inconclusive.19 Another
review of economic evaluations of acceptance‐ and mindfulness‐
based interventions reached a similar conclusions.18
With regard to specific economic evaluations of MBIs in
cancer patients, a study in 129 breast cancer patients suffering from
persistent pain explored cost‐effectiveness of MBCT compared with
wait‐list control with a time horizon of 6 months. When willingness‐
to‐pay (WTP) was €0, the MBCT intervention was cost‐effective with
a probability of 85%.20 Another study in 104 breast cancer patients
compared the cost‐effectiveness of mindfulness‐based stress reduc-
tion (MBSR) with wait‐list controls with a time horizon of 12 weeks.
MBSR was more costly ($+666) with an incremental QALY gain of
+0.03 compared with wait‐list controls, resulting in an ICER of
$22,200/QALY.21 Another study in 191 breast cancer patients inves-
tigated the cost‐effectiveness of mindfulness‐based art therapy
(MBAT) compared with an active support group with a time horizon
of 9 weeks. MBAT demonstrated the potential to achieve parity withthe support group intervention if some intervention‐related costs
were reduced.22
In short, the first studies demonstrate a tentatively positive, but
inconclusive view of the economic potential of MBIs. An economic
evaluation of an electronically delivered format of MBCT is yet to be
conducted. The primary aim of the current study was to evaluate the
cost‐effectiveness of both eMBCT and MBCT compared with TAU
from the societal perspective in the period from baseline (T0) to
post‐treatment (T1). The secondary aim was to explore costs and qual-
ity of life during the 9 month‐follow‐up (12‐month time horizon)
based on a linear extrapolation of TAU.2 | METHODS
2.1 | Trial design, participants, procedure
Study methods have been described in detail elsewhere.11 The pres-
ent study is an economic evaluation from a societal perspective
based on the results of a three‐armed multicentre, parallel group
RCT comparing the effectiveness of eMBCT and MBCT with TAU
in reducing psychological distress in cancer patients. As patients ran-
domized to TAU received either eMBCT or MBCT after 3 months,
the time horizon of the economic evaluation was restricted to 3
months.
Inclusion criteria were: a) any cancer diagnosis, current or past; b) a
score of ≥ 11 on the Hospital Anxiety and Depression Scale (HADS);c)
ability to attend MBCT both face‐to‐face and online; and d) good com-
mand of the Dutch language. Exclusion criteria were: a) severe psychi-
atric morbidity; b) change in psychotropic medication dosage within a
period of three months prior to baseline; c) current or previous partic-
ipation in ≥ 4 sessions of an MBI. Patients were recruited from April
2014 to December 2015 via self‐referral. The study was approved
by the ethical review board of the Radboud University Medical Center
(CMO Arnhem‐Nijmegen 2013/542) and all centres provided local
ethics approval. The study was registered on Clinicaltrials.gov
(NCT02138513), reported following CONSORT guidelines.23 A proto-
col paper was published in advance.24 All participants provided written
informed consent prior to enrolment.2.2 | Interventions
2.2.1 | Face‐to‐face MBCT
The MBCT protocol9 was followed except for slight tailoring to the
cancer patient. MBCT consisted of eight weekly 2.5h group sessions
guided by a therapist, a six‐hour one‐day silent retreat and daily home
practice assignments of about 45 minutes. All therapists in this study
were accredited in concordance with the UK Mindfulness‐Based
Teacher Trainer Network Good Practice Guidelines.
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The eMBCT was identical to MBCT in terms of content but was deliv-
ered individually and included weekly asynchronous written interac-
tion with a therapist over email. For more information, we refer to
our other work.11,152.3.1 | Treatment as usual
Treatment as usual (TAU) consisted of all healthcare patients wished
to receive. There were no restrictions on healthcare utilization during
the study period, except not participating in MBIs.2.4 | Measures
2.4.1 | Healthcare costs
TheTrimbos/iMTA questionnaire for Costs associated with Psychiatric
illness (TiC‐P)25 was used to collect information on direct healthcare
use and paid and informal work‐related productivity losses. The TiC‐
P is a self‐report instrument, but in the current study the TiC‐P was
administered by the researchers in an interview format. The recom-
mended time‐horizon for determining healthcare costs by TiC‐P of
three months was used.25
Direct healthcare costs were calculated by multiplying volumes of
care by standardized unit prices indexed using Dutch national price
indices to the 2016 price level26 (seeTable S1 in the Supporting Infor-
mation). Prescription medication costs were retrieved from the Dutch
national tariff list (https://www.medicijnkosten.nl). Societal costs were
calculated as the sum of medical and formal and informal productivity
loss costs for T1, T1+T2, and T1+T2+(T3*2), reaching a time horizon
of 12 months (9 months post‐treatment).2.4.2 | Indirect costs – paid and informal work‐
related productivity losses
Indirect costs due to paid work‐related productivity losses included
absenteeism and presenteeism costs. Absenteeism costs were calcu-
lated by multiplying the number of hours patients were absent from
their job by the gross wage per hour according to the Dutch guideline
for health economic evaluations.27 Presenteeism costs were calculated
by multiplying estimated number of work hours lost by gross wage per
hour. Indirect costs related to paid work‐related productivity losses
were calculated according to the Friction Cost method.28 Once
patients met the friction period criterium of >85 sick days at a specific
time point (starting count at baseline) no additional indirect costs due
to work were calculated during the rest of the study period. Indirect
costs related to productivity loss in informal work were also
included.27 The recall period for paid and informal work‐related pro-
ductivity losses was 4 weeks (as per default), which was proportion-
ately extrapolated from 4 weeks to 3 months to match the recall
period of the healthcare use questionnaire. Dutch national priceindices were used to index healthcare and productivity costs to the
2016 price level26 and costs were presented in Euros.
2.4.3 | Intervention costs
Additionally, intervention costs were €299.00 per person for patients
participating in the MBCT and €331.16 per person for patients partic-
ipating in eMBCT (see Table S2). In MBCT, travel and parking related
costs were calculated on an individual basis.27 Intervention develop-
ment costs were regarded as sunk costs and were therefore
disregarded because they would not need to be repeated if the inter-
vention were adopted on a broader scale.29
2.4.4 | Quality of life
To measure the health‐related quality of life (QoL) of cancer patients,
a validated health‐related QoL instrument was used: the EuroQol‐5D‐
3L (EQ‐5D).30,31 We chose to use a generic QoL measure as opposed
to a cancer‐specific measure such as the EORTC QLQ since we were
interested in measuring utilities.32 The EQ‐5D index is obtained by
applying predetermined weights to the five domains. This index gives
a societal‐based global utility score of the participant's health status
on a scale between‐.33 (worse than death) and 1 (perfect health).
From the utility scores at T0 and T1 QALYs were calculated for each
patient using the Area Under the Curve (AUC) method: ((EQ 5D T0
+ EQ 5D T1) /2) * (3/12) using the Dutch index tariff.31
2.5 | Linear extrapolation
One way to deal with extrapolation of a cost pattern is to assume a
linear relationship between costs and volume within some relevant
range. Within that relevant range, the total cost varies linearly with
volume, at least approximately. In terms of somatic care, patients
followed clinical routine with which we did not intervene and which
would remain similar after TAU. With regard to psychological care it
is known that psychological distress levels are associated with
healthcare consumption5 and these did not change in patients receiv-
ing TAU only.11 Therefore, the T1 measurement in TAU was linearly
extrapolated up to 12 months.
2.6 | Analyses
Descriptive analyses of mean differences between conditions were
tested by one‐way ANOVAs including treatment (eMBCT, MBCT or
TAU) as independent variable and costs/EQ‐5D utility scores/QALYs
as dependent variable on the complete‐case intention‐to‐treat (ITT)
sample. Analyses of follow‐up costs per category included costs at
baseline as a covariate. Post‐hoc tests were conducted by simple con-
trasts using TAU as reference group with Bonferroni‐corrected (due to
two comparisons with TAU) one‐sided P values (considering the posi-
tive clinical RCT) rendering P ≤.05 as significant. Because of baseline
differences in employment status, we conducted two separate analy-
ses, one including the employed‐at‐baseline subsample only and
COMPEN ET AL. 297another including baseline employment status as covariate. Cohen's d
effect sizes (ES) were calculated by dividing the difference in means by
baseline pooled SDs of the respective conditions33 and were
interpreted as small (0.2 to 0.5), medium (0.5 to 0.8), or large (.8).33
Cost‐utility analyses were conducted from the societal perspective
on the complete‐case ITT sample including all patients who filled‐out
the TiC‐P and EQ‐5D at T1, T2 and T3. The bootstrapped replications
(1000 iterations) were graphed on two cost‐utility planes (eMBCT vs.
TAU and MBCT vs. TAU). The horizontal axis of these planes repre-
sents the incremental effects and the vertical axis represents the
incremental costs. The QALY model assumes WTP= willingness to
accept compensation.
In addition, the net monetary benefit (NMB) was determined:
NMB=(effect E of intervention expressed in QALY * WTP) – costs C
for intervention. If the incremental NMB (ΔE * WTP ‐ ΔC) is > 0, the
intervention is considered to be cost‐effective compared with an
alternative. For the exact WTP is unknown, results of regression anal-
yses with the NMB as dependent variable were subsequently used to
obtain a cost‐effectiveness acceptability curve (CEAC) by plotting 1‐P/
2 against different levels of WTP (0, 20000, 40000, 60000, 80000) for
a QALY where P is the P value from the coefficient on the treatment
dummy variable in the regression analyses.343 | RESULTS
3.1 | Sample characteristics
In total, 245 self‐referred heterogeneous cancer patients with psycho-
logical distress were randomly assigned to eMBCT (n=90), MBCT
(n=77) or TAU (n=78) (See Figure 1). The three conditions did not dif-
fer in terms of baseline demographic or clinical characteristics (see
Table 1). Intervention dropout was significantly higher in the eMBCT
than in the MBCT group: (χ2(1, n=167)=3.92, P = .047). The three con-
ditions did not differ in employment status at baseline, although there
were differences at a descriptive level Of the patients who had a job at
baseline, relatively more patients met the friction period criterium in
both interventions compared with TAU, although this difference was
not significant (χ2(2, n=245)=5.25, P = .072) (see Table S3). During
the intervention period, a total of n=24 (33%) in eMBCT used a form
of mental healthcare compared with n=18 (29%) in MBCT and n=20
(32%) in TAU. This difference was not significant between conditions.
Study dropout (number of missing measurements at end of treatment)
did not differ between conditions. Study dropouts did not differ from
study completers in healthcare costs, informal work costs or EQ‐5D
utility scores at baseline. Study dropouts did have marginally signifi-
cantly lower paid work costs (P = .069) and societal costs (P = .065)
at baseline. Study dropouts were relatively more often non‐employed
patients compared with employed patients inTAU (P = .025) compared
with eMBCT and MBCT (P = ns), which further enhanced the differ-
ence in proportion of patients with a job between conditions included
in our analyses. Of all patients included in our analyses at end of treat-
ment, 56.9% in eMBCT, 53.1% in MBCT and 71.4% in TAU had a jobat baseline. Moreover, study dropouts demonstrated significantly
higher psychological distress scores compared with study completers
( F (1,244)=5.82, P = .017).
3.2 | Cost‐utility: 3 month time‐horizon
3.2.1 | Costs
Direct healthcare costs did not differ significantly between the two
intervention conditions and TAU (see Table 2). Costs associated with
paid work‐related productivity losses were lower in both eMBCT
and MBCT compared with TAU in post‐hoc comparisons (P = .014
and P = .002, respectively). Costs associated with informal work
did not differ significantly between conditions. Societal costs were
significantly lower in both eMBCT and MBCT compared with TAU
in post‐hoc comparisons (P = .002 and P = .014). Societal costs were
significantly lower in eMBCT vs TAU (M = ‐2457, SE = 856, P =
.005) and MBCT vs. TAU (M = ‐2998, SE = 904, P = .001) when
looking at the employed‐at‐baseline subsample only. Societal costs
were significantly lower in eMBCT vs TAU (M = ‐1836, SE = 615,
P = .003) and MBCT vs. TAU (M = ‐1394, SE = 594, P = .020) when
adjusting for baseline employment status.
3.2.2 | Quality of life
When QoL was expressed in EuroQol‐5D‐3L utility scores, patients in
the eMBCT and MBCT conditions reported significantly higher QoL at
T1 than patients in TAU ( F (2,198)=8.02, P < .001, see Table 2) with
moderate effect sizes (eMBCT vs. TAU=.54 and MBCT vs. TAU=.53)
. When QoL was expressed in QALYs, there was a non‐significant dif-
ference in favour of both interventions compared with TAU ( F (2,198)
=2.80, P = .063) with small to moderate effect sizes (eMBCT vs.
TAU=.37 and MBCT vs. TAU=.34).
3.2.3 | Cost‐utility
The cost‐utility planes (Figure 2) revealed that the vast majority cost‐
effective pairs are located in the south‐east quadrant where both
interventions are more effective and less costly than TAU, i.e., domi-
nate TAU. At a WTP of €20000 the mean incremental net monetary
benefit was €1916 (SD=€783) in eMBCT versus TAU and €2365
(SD=€796) in MBCT versus TAU. The cost‐effectiveness Acceptibility
Curve (CEAC) indicated that the probability of both interventions
being cost‐effective hovers around 99% regardless of the level of
WTP per QALY gained (see Figure S1).3.3 | Exploration of costs and quality of life during
the 9 month‐follow‐up
3.3.1 | Costs
Healthcare costs were significantly lower in eMBCT and MBCT com-
pared with TAU in (P = .035 and P = .048, respectively). Paid work‐
FIGURE 1 CONSORT flowchart of the cost‐
utility trial ran alongside clinical trial
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TABLE 1 Baseline sociodemographic and clinical characteristics (n=245)
Characteristic
All eMBCT MBCT TAU
n=245 n=90 n=77 n=78
n (%) n (%) n (%) n (%) P
Sex 0.912
Female 210 (85.7) 77 (85.6) 67 (87.0) 66 (84.6)
Male 35 (14.3) 13 (14.4) 10 (13.0) 12 (15.4)
Age, years 0.464
Mean 51.7 52.4 52.1 50.4
SD 10.7 10.7 11.4 9.9
Married/in a relationship 0.491
Yes 202 (82.4) 76 (84.4) 65 (84.4) 61 (78.2)
No 43 (17.6) 14 (15.6) 12 (15.6) 17 (21.8)
Children 0.314
Yes 169 (69.0) 65 (72.2) 48 (62.3) 56 (71.8)
No 76 (31.0) 25 (27.8) 29 (37.7) 22 (28.2)
Education 0.451
High 166 (67.8) 56 (62.2) 54 (70.1) 56 (71.8)
Middle 77 (31.4) 34 (37.8) 22 (28.6) 21(26.9)
Low 2 (0.8) 0 1 (1.3) 1(1.3)
Diagnosis 0.724
Breast cancer 151 (61.6) 53(58.9) 53 (68.8) 45 (57.7)
Gynecological cancer 18 (7.3) 9 (10.0) 2 (2.6) 7 (9.0)
Prostate cancer 16 (6.5) 7 (7.8) 6 (7.8) 3 (3.8)
Colon cancer 12 (4.9) 4 (4.4) 4 (5.2) 4 (5.1)
Non‐Hodgkin's lymphoma 11 (4.5) 3 (3.3) 1 (1.3) 7 (9.0)
Skin cancer 5 (2.0) 3 (3.3) 1 (1.3) 1 (1.3)
Thyroid cancer 4 (1.6) 1 (1.1) 1 (1.3) 2 (2.6)
Bladder cancer 4 (1.6) 2 (2.2) 1 (1.3) 1(1.3)
Neuroendocrine tumour 4 (1.6) 2 (2.2) 1 (1.3) 1 (1.3)
Other 20 (8.2) 6 (6.7) 7 (9.1) 7 (9.0)
Years since diagnosis 0.616
Mean 3.5 3.3 3.9 3.2
SD 4.7 4 5.7 4.3
Anticancer treatment intent 0.472
Curative 206 (84.1) 74 (82.2) 68 (88.3) 64 (82.1)
Palliative 39 (15.9) 16 (17.8) 9 (11.7) 14 (17.9)
Current treatment 0.694
None 133 (53.1) 49 (54.4) 43 (55.8) 41 (52.6)
Hormone therapy 79 (32.2) 28 (31.1) 22 (28.6) 29 (37.2)
Combination of treatments 12 (4.9) 4 (4.4) 4 (5.2) 4 (5.1)
Immunotherapy 9 (3.7) 5 (5.6) 1 (1.3) 3 (3.8)
Radiotherapy 8 (3.3) 3 (3.3) 5 (6.5) 0
Chemotherapy 4 (1.6) 1 (1.1) 2 (2.6) 1 (1.3)
COMPEN ET AL. 299related costs were significantly lower in both interventions com-
pared with TAU (both P ≤ .001). Informal work‐related costs weresignificantly lower in both interventions compared with TAU in
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FIGURE 2 Incremental cost‐effectiveness ratios (societal
perspective) for both intervention conditions versus TAU during
intervention period (T0‐T1)
COMPEN ET AL. 301significantly lower in both interventions compared with TAU (both P
≤ .001).3.3.2 | Quality of life
Patients in both interventions maintained the increased QoL over the
follow‐up period with no significant differences between eMBCT and
MBCT.4 | CONCLUSIONS
The aim of the current study was to evaluate the cost‐utility of both
eMBCT and MBCT compared with TAU from the societal perspective
in the period from baseline (T0) to post‐treatment (T1) and to explore
development of costs and quality of life during the 9 month‐follow‐up
results in the period from baseline to 9 month‐follow‐up (T3).
Healthcare costs and informal work‐related productivity losses did
not significantly differ between conditions, costs associated with paid
work were lower in the interventions compared with TAU. Impor-
tantly, the aggregated societal costs were significantly lower in both
interventions compared withTAU at all post‐treatment measurements
– despite the added intervention costs. Patients in the eMBCT and
MBCT conditions reported significantly higher QoL at T1 than patients
in TAU with moderate effect sizes, although there were no significant
differences between conditions in terms of QALYs. Since the NMB
was larger in MBCT than eMBCT, this implies that MBCT provides
most value for money compared with TAU. Extrapolated follow‐upresults demonstrated comparable favourable effects of both interven-
tions compared with TAU. However, it must be taken into account
that selective dropout hinder an unbiased inference of the effect of
both interventions in terms of societal costs. In theTAU condition, rel-
atively more patients without a job were lost‐to‐follow up. The results
must therefore be interpreted with caution and future studies should
preferably stratify for employment status.
Several psychosocial interventions have previously been demon-
strated to represent good value for money in cancer care.35 A review
of 11 cost‐effectiveness studies of psychosocial interventions in can-
cer care indicate cost‐effectiveness at different WTP thresholds, but
that more research is necessary and that more research should be per-
formed encompassing potential important cost drivers from a societal
perspective.36
The current results are partly in line with previous findings on cost‐
effectiveness of MBIs for cancer patients20-22 although it must be
noted that there are considerable differences between the studies in
terms of population, intervention, measures and analysis perspective.
Moreover, the current sample was self‐referred.4.1 | Study limitations
The most important limitation is lack of follow‐up for TAU. As cancer
patients might recover spontaneously from psychological distress, it
might not be appropriate to assume that costs and QoL remained sta-
ble over time. However, our sample consisted of cancer patients on
average 3.5 years post diagnosis, rendering them less likely to recover
spontaneously.37 Moreover, our period of “watchful waiting” took well
over the usual period of “watchful waiting” in other studies, e.g.38
Therefore, we considered it justified to extrapolate TAU from T1.4.2 | Clinical implications
These results imply that offering Internet‐based MBCT in clinical prac-
tice improves accessibility of psycho‐oncological care whilst saving
societal costs, without compromising intervention efficacy.
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